AngioDynamics Company Leadership
ANGO Stock | USD 6.99 0.16 2.34% |
AngioDynamics' insiders are aggressively buying. The analysis of insiders' sentiment of trading AngioDynamics stock suggests that virtually all insiders are extremely bullish at this time. AngioDynamics employs about 748 people. The company is managed by 13 executives with a total tenure of roughly 50 years, averaging almost 3.0 years of service per executive, having 57.54 employees per reported executive.
James Clemmer CEO President CEO, Director |
Chad Campbell President Senior Vice President and General Manager, Vascular Access |
AngioDynamics' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2024-10-10 | Warren Nighan Jr | Acquired 100 @ 6.08 | View | ||
2024-10-08 | Stephen A Trowbridge | Acquired 1700 @ 5.86 | View | ||
2024-10-07 | Warren Nighan Jr | Acquired 768 @ 6.09 | View | ||
2024-04-08 | James C Clemmer | Acquired 10000 @ 6.7 | View |
Monitoring AngioDynamics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
AngioDynamics |
AngioDynamics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AngioDynamics' future performance. Based on our forecasts, it is anticipated that AngioDynamics will maintain a workforce of about 750 employees by December 2024.AngioDynamics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0612) % which means that it has lost $0.0612 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7785) %, meaning that it created substantial loss on money invested by shareholders. AngioDynamics' management efficiency ratios could be used to measure how well AngioDynamics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to grow to -0.73. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, AngioDynamics' Debt To Assets are very stable compared to the past year.As of the 26th of November 2024, Common Stock Shares Outstanding is likely to drop to about 30 M. In addition to that, Net Loss is likely to grow to about (44.8 M)
AngioDynamics Workforce Comparison
AngioDynamics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 69,029. AngioDynamics claims roughly 748 in number of employees contributing just under 2% to equities under Health Care industry.
AngioDynamics Profit Margins
The company has Profit Margin (PM) of (0.83) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.13) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.13.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.59 | 0.509 |
|
|
AngioDynamics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AngioDynamics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 1.7 | 34 | 20 | 1,056,757 | 63,960 |
2023-09-01 | 0.881 | 37 | 42 | 1,361,559 | 450,619 |
2022-09-01 | 1.8667 | 28 | 15 | 220,408 | 121,779 |
2022-06-01 | 0.2 | 1 | 5 | 6,022 | 23,057 |
2022-03-01 | 1.0 | 2 | 2 | 11,000 | 1,777 |
2021-12-01 | 0.3333 | 2 | 6 | 22,748 | 49,943 |
2021-09-01 | 0.9796 | 48 | 49 | 726,626 | 388,157 |
2021-06-01 | 0.4 | 2 | 5 | 19,351 | 36,552 |
2021-03-01 | 1.0 | 2 | 2 | 73,000 | 7,027 |
2020-09-01 | 1.0 | 22 | 22 | 661,809 | 101,791 |
2020-03-01 | 1.0 | 2 | 2 | 23,580 | 980.00 |
2019-12-01 | 7.0 | 7 | 1 | 108,408 | 736.00 |
2019-09-01 | 0.75 | 30 | 40 | 549,233 | 448,351 |
2019-06-01 | 0.2857 | 2 | 7 | 13,300 | 27,096 |
2018-09-01 | 1.7857 | 25 | 14 | 292,745 | 24,178 |
2018-06-01 | 0.4 | 4 | 10 | 41,650 | 67,931 |
2017-12-01 | 0.6 | 3 | 5 | 41,409 | 79,691 |
2017-09-01 | 1.8421 | 35 | 19 | 453,386 | 166,882 |
2017-06-01 | 0.0455 | 1 | 22 | 14,000 | 4,862,567 |
2017-03-01 | 0.5 | 1 | 2 | 14,000 | 28,000 |
2016-12-01 | 0.3333 | 2 | 6 | 50,000 | 5,000,000 |
2016-09-01 | 1.2727 | 28 | 22 | 389,948 | 4,624,865 |
2016-06-01 | 0.75 | 3 | 4 | 500,000 | 17,806 |
2015-09-01 | 1.1143 | 39 | 35 | 429,609 | 125,124 |
2015-06-01 | 2.0 | 2 | 1 | 19,649 | 4,649 |
2015-03-01 | 0.3333 | 1 | 3 | 18,100 | 36,619 |
2014-09-01 | 1.8 | 36 | 20 | 416,843 | 43,453 |
2014-06-01 | 1.0 | 2 | 2 | 16,500 | 16,448 |
2013-12-01 | 2.8571 | 20 | 7 | 212,407 | 52,693 |
2013-09-01 | 2.0625 | 33 | 16 | 331,424 | 24,965 |
2013-03-01 | 3.0 | 9 | 3 | 216,808 | 5,946 |
2012-12-01 | 0.3846 | 5 | 13 | 68,000 | 36,718 |
2012-09-01 | 3.0 | 33 | 11 | 268,247 | 14,955 |
2012-06-01 | 3.6667 | 11 | 3 | 104,209 | 4,589 |
2012-03-01 | 0.5455 | 6 | 11 | 103,000 | 42,916 |
2011-12-01 | 4.0 | 4 | 1 | 322,500 | 200,000 |
2011-09-01 | 3.7143 | 26 | 7 | 629,617 | 12,483 |
2011-06-01 | 1.0 | 1 | 1 | 2,091 | 2,091 |
2011-03-01 | 2.5 | 5 | 2 | 103,000 | 10,119 |
2010-12-01 | 2.5 | 5 | 2 | 151,000 | 50,000 |
2010-09-01 | 1.8333 | 22 | 12 | 295,250 | 75,702 |
2010-06-01 | 3.0 | 3 | 1 | 52,591 | 2,091 |
2010-03-01 | 0.5 | 2 | 4 | 4,500 | 306,298 |
2009-12-01 | 0.8 | 4 | 5 | 55,628 | 25,152 |
2009-09-01 | 11.5 | 23 | 2 | 226,709 | 50,800 |
2009-06-01 | 3.0 | 3 | 1 | 9,091 | 2,091 |
2009-03-01 | 2.0 | 10 | 5 | 399,693 | 22,267 |
2008-12-01 | 1.0 | 1 | 1 | 21,000 | 0.00 |
2008-09-01 | 18.0 | 18 | 1 | 151,313 | 20,000 |
2008-06-01 | 3.0 | 3 | 1 | 6,106 | 2,091 |
2008-03-01 | 2.0 | 2 | 1 | 5,000 | 2,000 |
2007-09-01 | 13.5 | 27 | 2 | 239,775 | 10,200 |
2007-06-01 | 1.0 | 4 | 4 | 53,500 | 12,368 |
2007-03-01 | 0.1176 | 2 | 17 | 5,955 | 71,743 |
2006-12-01 | 0.5333 | 8 | 15 | 185,546 | 173,159 |
2006-09-01 | 0.7619 | 16 | 21 | 61,993 | 58,182 |
2006-06-01 | 0.5714 | 8 | 14 | 12,624 | 23,686 |
2006-03-01 | 0.5 | 11 | 22 | 30,500 | 59,000 |
2005-12-01 | 0.3421 | 13 | 38 | 20,062 | 63,124 |
2005-09-01 | 0.5517 | 16 | 29 | 78,900 | 62,112 |
2005-06-01 | 0.6296 | 17 | 27 | 51,838 | 53,103 |
2005-03-01 | 0.5 | 11 | 22 | 28,546 | 57,092 |
2004-12-01 | 1.3333 | 8 | 6 | 1,735,843 | 9,242,006 |
2004-06-01 | 1.1667 | 7 | 6 | 78,400 | 99,319 |
AngioDynamics Notable Stakeholders
An AngioDynamics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AngioDynamics often face trade-offs trying to please all of them. AngioDynamics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AngioDynamics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
James Clemmer | President CEO, Director | Profile | |
Chad Campbell | Senior Vice President and General Manager, Vascular Access | Profile | |
David Helsel | Senior Vice President - Global Operations | Profile | |
Warren Nighan | Senior Vice President-Senior Vice President Quality & Regulatory Affairs | Profile | |
Kim Seabury | Senior Vice President Information Technology | Profile | |
Benjamin Davis | Senior Vice President Business Development | Profile | |
Stephen Trowbridge | Sr. VP, General Counsel and Assistant Secretary | Profile | |
Laura Piccinini | Senior International | Profile | |
Scott Centea | Senior Therapies | Profile | |
Richard Rosenzweig | Gen VP | Profile | |
Marna BronfenMoore | Senior Resources | Profile | |
Juan Serna | Senior Affairs | Profile | |
Saleem Cheeks | Vice Communications | Profile |
About AngioDynamics Management Performance
The success or failure of an entity such as AngioDynamics often depends on how effective the management is. AngioDynamics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AngioDynamics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AngioDynamics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.77) | (0.73) | |
Return On Capital Employed | (0.43) | (0.41) | |
Return On Assets | (0.58) | (0.55) | |
Return On Equity | (0.90) | (0.85) |
AngioDynamics Workforce Analysis
Traditionally, organizations such as AngioDynamics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AngioDynamics within its industry.AngioDynamics Manpower Efficiency
Return on AngioDynamics Manpower
Revenue Per Employee | 406.3K | |
Revenue Per Executive | 23.4M | |
Net Loss Per Employee | 246.5K | |
Net Loss Per Executive | 14.2M | |
Working Capital Per Employee | 136.5K | |
Working Capital Per Executive | 7.9M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 7.249 | Quarterly Revenue Growth (0.14) | Return On Assets (0.06) | Return On Equity (0.78) |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.